High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
IP Group PLC (FRA:IOOA) grew NAV per share to 114p and generated GBP69 million in H1 2026 cash proceeds, more than doubling last year's first-half total.
Key Stats for PFE StockPast week performance: Consolidating52-week range: $24 to $29Valuation model target price: $28Implied upside: 2. 8% over 2.
IP Group (LON:IPO) reported higher net asset value, strong cash realizations and broad portfolio activity in the first half of 2026, while management said it remains focused on converting portfolio value into shareholder returns. Net asset value per share increased 3.2% during the half year to 114p
Pfizer stock has quietly put up a 25.6% gain over the past year, yet broad valuation checks still do not flag it as either clearly cheap or clearly expensive. With mixed signals on value and fresh product news in the background, investors are weighing how much of the recent optimism is already reflected in the share price. The 25.6% 1 year return suggests sentiment toward Pfizer has improved meaningfully, which raises the bar for further upside driven purely by valuation. Approval of Pfizer...
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pfizer stock has delivered a roughly 28% decline over the past five years, yet recent gains and a mixed set of valuation checks mean the current price is not an obvious bargain or clear bubble. With fresh product news and shifting expectations around its portfolio, investors are weighing whether the recent rebound leaves enough room for attractive long term returns. The share price is down about 28% over five years. This points to a company that has yet to fully reward long term holders...
Three Pfizer insiders executed transactions directly on the heels of the drugmaker’s second-quarter earnings report.
Valneva (NASDAQ:VALN) reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and expectations for regulatory progress on its Lyme disease vaccine candidate with Pfizer. CEO Thomas Lingelbac
In early August 2026, Pfizer Inc. reported second-quarter results showing revenue of US$15,034 million and a net loss of US$248 million, alongside US$4.30 billion in non-cash intangible asset impairments and a modest increase in full-year 2026 revenue guidance to US$60.50–US$62.50 billion. A key offsetting highlight was the positive Phase 3 data for Pfizer’s autoimmune drug LITFULO in nonsegmental vitiligo, underlining the growing importance of its non-COVID portfolio and broader immunology...
Moby summary of Spero Therapeutics, Inc.'s Q2 2026 earnings call
SPRO strengthens its balance sheet and extends cash runway into 2029 while advancing its new SP001 immunology pipeline following the landmark approval of the first oral carbapenem antibiotic.
Pfizer’s second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company’s performance was shaped by strong execution in its non-COVID portfolio, with management highlighting robust revenue contributions from acquired brands and recent launches. CEO Albert Bourla attributed operational progress to “continued strategic progress” and emphasized the value generated by recent acquisitions such as Seagen and Biohaven. Management
This problem has a solution, and Pfizer is implementing it.
BBIO's Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled, fueling growth and pipeline advances.
Non-COVID products surge 5% as Pfizer raises guidance and targets $9.7B in savings.
The stock's 6.4% yield is attractive, but it comes with risk.
Novavax beat Q2 earnings and revenue estimates, raises its 2026 adjusted revenue outlook, cuts expense guidance and outlines potential Sanofi milestones ahead.
Novavax secures key partnerships and raises 2026 outlook while advancing its adjuvant platform in infectious disease and oncology.
Pfizer carries one of Big Pharma's fattest yields while Merck burns cash on deals to secure its next growth era. Which trade-off actually serves income investors better after both companies reported earnings?
Pfizer (PFE) is back in focus after its second quarter 2026 update, which paired a reported net loss and sizeable non cash impairments with higher full year revenue guidance and solid non COVID product performance. See our latest analysis for Pfizer. The latest results and raised revenue guidance have lifted sentiment toward Pfizer, with the stock showing a 1 month share price return of 8.81% and a 1 year total shareholder return of 15.42%, although longer term total shareholder returns...
Pfizer increased its savings target and revenue outlook, but investors remained focused on patent expirations and pipeline execution.
PFE raises its 2026 revenue outlook as non-COVID growth, deeper cost cuts and pipeline catalysts offset weaker COVID demand.
Pfizer (NYSE:PFE) reported second-quarter 2026 revenue of $15 billion and adjusted diluted earnings per share of $0.77, with management saying both measures exceeded its internal expectations. Revenue increased 1% operationally from a year earlier, while revenue excluding COVID-19 products rose 5% o
Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
Moby summary of Pfizer Inc.'s Q2 2026 earnings call
The quarter exposed where Pfizer's recovery is really coming from
Fuelled by blockbusters such as Eliquis, Pfizer is cementing its post-Covid revenue legacy.
Pfizer beats Q2 earnings and revenue estimates, raises the low end of its 2026 sales outlook, but lowers expectations for COVID product revenues.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
